{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:46:03Z","timestamp":1794638763348,"version":"4.9.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia\/lymphoma (ATLL) is an intractable hematologic malignancy caused by human T-lymphotropic virus type 1 (HTLV-1), which infects approximately 20 million people worldwide. Here, we have explored the possible expression of cancer\/testis (CT) antigens by ATLL cells, as CT antigens are widely recognized as ideal targets of cancer immunotherapy against solid tumors. A high percentage (87.7%) of ATLL cases (n = 57) expressed CT antigens at the mRNA level: NY-ESO-1 (61.4%), MAGE-A3 (31.6%), and MAGE-A4 (61.4%). CT antigen expression was confirmed by immunohistochemistry. This contrasts with other types of lymphoma or leukemia, which scarcely express these CT antigens. Humoral immune responses, particularly against NY-ESO-1, were detected in 11.6% (5 of 43) and NY-ESO-1\u2013specific CD8+ T-cell responses were observed in 55.6% (5 of 9) of ATLL patients. NY-ESO-1\u2013specific CD8+ T cells recognized autologous ATLL cells and produced effector cytokines. Thus, ATLL cells characteristically express CT antigens and therefore vaccination with CT antigens can be an effective immunotherapy of ATLL.<\/jats:p>","DOI":"10.1182\/blood-2011-09-379982","type":"journal-article","created":{"date-parts":[[2012,2,9]],"date-time":"2012-02-09T12:10:11Z","timestamp":1328789411000},"page":"3097-3104","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":59,"title":["Cancer\/testis antigens are novel targets of immunotherapy for adult T-cell leukemia\/lymphoma"],"prefix":"10.1182","volume":"119","author":[{"given":"Hiroyoshi","family":"Nishikawa","sequence":"first","affiliation":[{"name":"Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Maeda","sequence":"additional","affiliation":[{"name":"Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Gnjatic","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Fukumori","sequence":"additional","affiliation":[{"name":"Osaka Blood Center, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Inagaki","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd J.","family":"Old","sequence":"additional","affiliation":[{"name":"Ludwig Institute for Cancer Research, New York Branch, Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka, Japan;"},{"name":"Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111808021359400_B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.bloodjournal503481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases.","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"issue":"4","key":"2019111808021359400_B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation.","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2019111808021359400_B3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CMR.00063-09","article-title":"Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases.","volume":"23","author":"Goncalves","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"2019111808021359400_B4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0090-1229(78)90005-3","article-title":"Effect of adult T-cell leukemia cells on pokeweed mitogen-induced normal B-cell differentiation.","volume":"10","author":"Uchiyama","year":"1978","journal-title":"Clin Immunol Immunopathol"},{"issue":"11","key":"2019111808021359400_B5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","article-title":"Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.","volume":"16","author":"Yagi","year":"2004","journal-title":"Int Immunol"},{"issue":"3","key":"2019111808021359400_B6","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/sj.leu.2403628","article-title":"Phenotypic and functional relationship between adult T-cell leukemia cells and regulatory T cells.","volume":"19","author":"Matsubara","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"2019111808021359400_B7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/intimm\/dxh366","article-title":"Regulatory T cell-like activity of Foxp3+ adult T cell leukemia cells.","volume":"18","author":"Chen","year":"2006","journal-title":"Int Immunol"},{"issue":"1","key":"2019111808021359400_B8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1349-7006.2010.01767.x","article-title":"Immunopathogenesis of lymphoma: focus on CCR4.","volume":"102","author":"Ishida","year":"2011","journal-title":"Cancer Sci"},{"issue":"2","key":"2019111808021359400_B9","doi-asserted-by":"crossref","first-page":"e1001274","DOI":"10.1371\/journal.ppat.1001274","article-title":"HTLV-1 bZIP factor induces T-cell lymphoma and systemic inflammation in vivo.","volume":"7","author":"Satou","year":"2011","journal-title":"PLoS Pathog"},{"issue":"34","key":"2019111808021359400_B10","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808021359400_B11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an International Consensus Meeting.","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111808021359400_B12","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study.","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111808021359400_B13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ijc.20007","article-title":"Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells.","volume":"109","author":"Takeda","year":"2004","journal-title":"Int J Cancer"},{"issue":"8","key":"2019111808021359400_B14","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1099\/vir.0.010199-0","article-title":"HBZ is an immunogenic protein, but not a target antigen, for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes.","volume":"90","author":"Suemori","year":"2009","journal-title":"J Gen Virol"},{"issue":"2","key":"2019111808021359400_B15","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nm1718","article-title":"Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma.","volume":"14","author":"Verhasselt","year":"2008","journal-title":"Nat Med"},{"issue":"3","key":"2019111808021359400_B16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1349-7006.2008.01054.x","article-title":"Impaired Tax-specific T-cell responses with insufficient control of HTLV-1 in a subgroup of individuals at asymptomatic and smoldering stages.","volume":"100","author":"Shimizu","year":"2009","journal-title":"Cancer Sci"},{"issue":"8","key":"2019111808021359400_B17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer.","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2019111808021359400_B18","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/testis (CT) antigens: potential targets for immunotherapy.","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci"},{"key":"2019111808021359400_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen.","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res"},{"key":"2019111808021359400_B20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1146\/annurev.immunol.021908.132544","article-title":"Immune therapy for cancer.","volume":"27","author":"Dougan","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2019111808021359400_B21","first-page":"167","article-title":"Differential expression of cancer testis genes in histological subtypes of non-Hodgkin's lymphomas.","volume":"9","author":"Xie","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111808021359400_B22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/ijc.11623","article-title":"mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies.","volume":"108","author":"Greiner","year":"2004","journal-title":"Int J Cancer"},{"issue":"3","key":"2019111808021359400_B23","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87).","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111808021359400_B24","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome.","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111808021359400_B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2008.01038.x","article-title":"Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.","volume":"100","author":"Ri","year":"2009","journal-title":"Cancer Sci"},{"issue":"8","key":"2019111808021359400_B26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","article-title":"A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.","volume":"187","author":"Stockert","year":"1998","journal-title":"J Exp Med"},{"issue":"5","key":"2019111808021359400_B27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<749::AID-IJC24>3.0.CO;2-O","article-title":"Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family.","volume":"86","author":"Rimoldi","year":"2000","journal-title":"Int J Cancer"},{"issue":"22","key":"2019111808021359400_B28","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer.","volume":"11","author":"Gure","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2019111808021359400_B29","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1073\/pnas.0914213107","article-title":"Seromic profiling of ovarian and pancreatic cancer.","volume":"107","author":"Gnjatic","year":"2010","journal-title":"Proc Natl Acad of Sci U S A"},{"issue":"3","key":"2019111808021359400_B30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2005-02-0607","article-title":"CD4+CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T-cell responses in cancer patients.","volume":"106","author":"Nishikawa","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2019111808021359400_B31","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1172\/JCI28045","article-title":"In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.","volume":"116","author":"Nishikawa","year":"2006","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111808021359400_B32","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7","article-title":"A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.","volume":"29","author":"Duffour","year":"1999","journal-title":"Eur J Immunol"},{"issue":"3","key":"2019111808021359400_B33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage.","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"43","key":"2019111808021359400_B34","doi-asserted-by":"crossref","first-page":"37077","DOI":"10.1074\/jbc.M111.280123","article-title":"Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo.","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111808021359400_B35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2004.04999.x","article-title":"Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia\/lymphoma cells.","volume":"126","author":"Karube","year":"2004","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111808021359400_B36","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/ijc.22536","article-title":"Regulatory T-cell function of adult T-cell leukemia\/lymphoma cells.","volume":"120","author":"Yano","year":"2007","journal-title":"Int J Cancer"},{"issue":"4","key":"2019111808021359400_B37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.25429","article-title":"Regulatory T cells in tumor immunity.","volume":"127","author":"Nishikawa","year":"2010","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111808021359400_B38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4049\/jimmunol.0903846","article-title":"Human T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.","volume":"185","author":"Toulza","year":"2010","journal-title":"J Immunol"},{"issue":"9","key":"2019111808021359400_B39","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111808021359400_B40","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.194.6.847","article-title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+ regulatory T cells.","volume":"194","author":"Iellem","year":"2001","journal-title":"J Exp Med"},{"issue":"22","key":"2019111808021359400_B41","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma.","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111808021359400_B42","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study [published online ahead of print February 6, 2012].","author":"Ishida","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808021359400_B43","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1158\/0008-5472.CAN-03-1452","article-title":"Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation.","volume":"64","author":"Harashima","year":"2004","journal-title":"Cancer Res"},{"issue":"25","key":"2019111808021359400_B44","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1.","volume":"358","author":"Hunder","year":"2008","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111808021359400_B45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.","volume":"29","author":"Robbins","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111808021359400_B46","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified.","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111808021359400_B47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-08-1808","article-title":"Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult T-cell leukemia\/lymphoma.","volume":"15","author":"Nakagawa","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111808021359400_B48","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2019111808021359400_B49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1349-7006.2005.00050.x","article-title":"Tumor immunity against adult T-cell leukemia.","volume":"96","author":"Kannagi","year":"2005","journal-title":"Cancer Sci"},{"issue":"6024","key":"2019111808021359400_B50","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3097\/1349792\/zh801312003097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/13\/3097\/1349792\/zh801312003097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T06:28:27Z","timestamp":1713508107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/13\/3097\/29655\/Cancertestis-antigens-are-novel-targets-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,29]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,3,29]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-09-379982","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,29]]}}}